Drug side effects
Selective COX-2 inhibitors linked to worse outcomes after ischaemic stroke
Source: Shutterstock.com
Risk of ischaemic stroke is known to be increased by the use of selective cyclooxygenase-2 inhibitors
Non-steroidal anti-inflammatory drugs (NSAIDs) include non-selective and selective cyclooxygenase (COX)-2 inhibitors. Selective COX-2 inhibitors have been found to increase the risk of ischaemic stroke; new research suggests that these drugs also herald worse outcomes following ischaemic stroke.
Writing in Neurology (online, 5 November 2014)[1], Morten Schmidt, from Aarhus University Hospital Denmark, and colleagues report a cohort study involving 100,043 people admitted to hospital with a first stroke. Current use of a COX-2 inhibitor was associated with increased mortality at 30 days versus non-use (adjusted hazard ratio 1.19, 95% confidence interval 1.02–1.38). The risk increase was confined to older drugs such as etodolac and diclofenac.
“Our study adds to the increasing body of evidence concerning the vascular risk and prognostic impact associated with use of COX-2 inhibitors,” write Schmidt and co-authors.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067193
Recommended from Pharmaceutical Press
- Previous
- Next
Introduction to Clinical Pharmaceutics (An)
This unique textbook covers the role of basic pharmaceutics in clinical outcomes and in explaining the behaviour of medicines in the body.
£27.00Buy now
Integrated Pharmacy Case Studies
Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.
£47.00Buy now
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.